Journal Article
. 2009 Jul; 206(8):1717-25.
doi: 10.1084/jem.20082492.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Karl S Peggs 1 Sergio A Quezada  Cynthia A Chambers  Alan J Korman  James P Allison  
  • PMID: 19581407
  •     33 References
  •     383 citations


Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma, the critical cellular targets for their activity remains unclear. In particular, debate has focused on whether the effector T cell (T(eff)) or regulatory T cell (T reg cell) compartment is the primary target of antibody-mediated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show that although blockade on effector cells significantly improves tumor protection, unicompartmental blockade on regulatory cells completely fails to enhance antitumor responses. However, concomitant blockade of both compartments leads to a synergistic effect and maximal antitumor activity. We conclude that the combination of direct enhancement of T(eff) cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti-CTLA-4 antibodies during cancer immunotherapy.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Karl S Peggs, Sergio A Quezada, James P Allison.
Immunol Rev, 2008 Sep 02; 224. PMID: 18759925
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
Kenneth D Lute, Kenneth F May, +8 authors, Yang Liu.
Blood, 2005 Jul 23; 106(9). PMID: 16037385    Free PMC article.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
CTLA-4 regulates induction of anergy in vivo.
R J Greenwald, V A Boussiotis, +2 authors, A H Sharpe.
Immunity, 2001 Mar 10; 14(2). PMID: 11239447
Highly Cited.
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
R P Sutmuller, L M van Duivenvoorde, +6 authors, C J Melief.
J Exp Med, 2001 Sep 19; 194(6). PMID: 11560997    Free PMC article.
Highly Cited.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.
Sergio A Quezada, Karl S Peggs, +3 authors, James P Allison.
J Exp Med, 2008 Aug 30; 205(9). PMID: 18725522    Free PMC article.
Highly Cited.
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
S Read, V Malmström, F Powrie.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899916    Free PMC article.
Highly Cited.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
CTLA-4 regulates cell cycle progression during a primary immune response.
Rebecca J Greenwald, Mariette A Oosterwegel, +4 authors, Arlene H Sharpe.
Eur J Immunol, 2002 Jan 25; 32(2). PMID: 11807776
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
S Onizuka, I Tawara, +3 authors, E Nakayama.
Cancer Res, 1999 Jul 09; 59(13). PMID: 10397255
Highly Cited.
Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.
Z Chen, S B Koralov, G Kelsoe.
J Exp Med, 2000 Nov 09; 192(9). PMID: 11067882    Free PMC article.
ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells.
Josef Bodor, Zoltan Fehervari, Betty Diamond, Shimon Sakaguchi.
Eur J Immunol, 2007 Mar 21; 37(4). PMID: 17372992
Modulation of tryptophan catabolism by regulatory T cells.
Francesca Fallarino, Ursula Grohmann, +7 authors, Paolo Puccetti.
Nat Immunol, 2003 Oct 28; 4(12). PMID: 14578884
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
D A Mandelbrot, A J McAdam, A H Sharpe.
J Exp Med, 1999 Jan 20; 189(2). PMID: 9892625    Free PMC article.
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
M F Bachmann, G Köhler, +2 authors, M Kopf.
J Immunol, 1999 Jul 22; 163(3). PMID: 10415006
Thymocyte development is normal in CTLA-4-deficient mice.
C A Chambers, D Cado, T Truong, J P Allison.
Proc Natl Acad Sci U S A, 1997 Aug 19; 94(17). PMID: 9256476    Free PMC article.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.
C A Chambers, M S Kuhns, J P Allison.
Proc Natl Acad Sci U S A, 1999 Jul 21; 96(15). PMID: 10411922    Free PMC article.
Molecular interactions mediating T cell antigen recognition.
P Anton van der Merwe, Simon J Davis.
Annu Rev Immunol, 2003 Mar 05; 21. PMID: 12615890
Highly Cited. Review.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, +6 authors, T W Mak.
Science, 1995 Nov 10; 270(5238). PMID: 7481803
Highly Cited.
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells.
C A Chambers, T J Sullivan, T Truong, J P Allison.
Eur J Immunol, 1998 Nov 10; 28(10). PMID: 9808182
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered.
M F Bachmann, A Gallimore, +3 authors, M Kopf.
Eur J Immunol, 2001 Feb 17; 31(2). PMID: 11180109
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells.
Lalitha Vijayakrishnan, Jacqueline M Slavik, +9 authors, Vijay K Kuchroo.
Immunity, 2004 May 15; 20(5). PMID: 15142525
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
B M Carreno, F Bennett, +5 authors, J Madrenas.
J Immunol, 2000 Jul 21; 165(3). PMID: 10903737
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.
Simon Read, Rebecca Greenwald, +5 authors, Fiona Powrie.
J Immunol, 2006 Sep 20; 177(7). PMID: 16982872    Free PMC article.
Highly Cited.
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Silvia Piconese, Barbara Valzasina, Mario P Colombo.
J Exp Med, 2008 Mar 26; 205(4). PMID: 18362171    Free PMC article.
Highly Cited.
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
P Shrikant, A Khoruts, M F Mescher.
Immunity, 1999 Nov 05; 11(4). PMID: 10549630
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
T Takahashi, T Tagami, +5 authors, S Sakaguchi.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899917    Free PMC article.
Highly Cited.
Immune tolerance induction by integrating innate and adaptive immune regulators.
Jun Suzuki, Camillo Ricordi, Zhibin Chen.
Cell Transplant, 2009 Nov 19; 19(3). PMID: 19919733    Free PMC article.
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
Lana E Kandalaft, Nathan Singh, +4 authors, George Coukos.
Gynecol Oncol, 2009 Dec 05; 116(2). PMID: 19959212    Free PMC article.
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
Jianda Yuan, David B Page, +14 authors, Jedd D Wolchok.
Cancer Immun, 2010 Jan 08; 10. PMID: 20052966    Free PMC article.
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
Sergio A Quezada, Tyler R Simpson, +9 authors, James P Allison.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156971    Free PMC article.
Highly Cited.
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
Ying Xie, Akgül Akpinarli, +6 authors, Paul Andrew Antony.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156973    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Cancer vaccine by fusions of dendritic and cancer cells.
Shigeo Koido, Eiichi Hara, +4 authors, Hisao Tajiri.
Clin Dev Immunol, 2010 Feb 26; 2009. PMID: 20182533    Free PMC article.
Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Louis M Weiner, Rishi Surana, Shangzi Wang.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414205    Free PMC article.
Highly Cited. Review.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
Directing dendritic cell immunotherapy towards successful cancer treatment.
Rachel Lubong Sabado, Nina Bhardwaj.
Immunotherapy, 2010 May 18; 2(1). PMID: 20473346    Free PMC article.
Dendritic cell subsets as vectors and targets for improved cancer therapy.
Karolina Palucka, Hideki Ueno, +2 authors, Jacques Banchereau.
Curr Top Microbiol Immunol, 2010 May 22; 344. PMID: 20490776    Free PMC article.
Modulation of CTLA-4 and GITR for cancer immunotherapy.
Francesca Avogadri, Jianda Yuan, +2 authors, Jedd D Wolchok.
Curr Top Microbiol Immunol, 2010 Jun 22; 344. PMID: 20563707    Free PMC article.
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.
Akshata Udyavar, Terrence L Geiger.
Arch Immunol Ther Exp (Warsz), 2010 Aug 04; 58(5). PMID: 20680493    Free PMC article.
Dendritic cells: are they clinically relevant?
Karolina Palucka, Hideki Ueno, +2 authors, Jacques Banchereau.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693842    Free PMC article.
CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Jiehua Zhou, Asad Bashey, +9 authors, Edward D Ball.
Biol Blood Marrow Transplant, 2010 Aug 18; 17(5). PMID: 20713164    Free PMC article.
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.
Maya Eisenring, Johannes vom Berg, +2 authors, Burkhard Becher.
Nat Immunol, 2010 Oct 12; 11(11). PMID: 20935648
IL-35-mediated induction of a potent regulatory T cell population.
Lauren W Collison, Vandana Chaturvedi, +13 authors, Dario A A Vignali.
Nat Immunol, 2010 Oct 19; 11(12). PMID: 20953201    Free PMC article.
Highly Cited.
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Yael S Barach, Jun Sik Lee, Xingxing Zang.
Trends Mol Med, 2010 Oct 26; 17(1). PMID: 20971039    Free PMC article.
Designing vaccines based on biology of human dendritic cell subsets.
Karolina Palucka, Jacques Banchereau, Ira Mellman.
Immunity, 2010 Oct 30; 33(4). PMID: 21029958    Free PMC article.
Highly Cited. Review.
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Margaret K Callahan, Jedd D Wolchok, James P Allison.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074063    Free PMC article.
LAG-3 in Cancer Immunotherapy.
Monica V Goldberg, Charles G Drake.
Curr Top Microbiol Immunol, 2010 Nov 19; 344. PMID: 21086108    Free PMC article.
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.
Scott E Kern, Chanjuan Shi, Ralph H Hruban.
J Pathol, 2010 Dec 03; 223(2). PMID: 21125682    Free PMC article.
Dendritic cells and immunity against cancer.
K Palucka, H Ueno, J Fay, J Banchereau.
J Intern Med, 2010 Dec 17; 269(1). PMID: 21158979    Free PMC article.
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance.
Virginia A Pedicord, Welby Montalvo, Ingrid M Leiner, James P Allison.
Proc Natl Acad Sci U S A, 2010 Dec 22; 108(1). PMID: 21173239    Free PMC article.
Therapeutic cancer vaccines: are we there yet?
Christopher A Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P Restifo.
Immunol Rev, 2011 Jan 05; 239(1). PMID: 21198663    Free PMC article.
Highly Cited. Review.
Recent developments in cancer vaccines.
Karolina Palucka, Hideki Ueno, Jacques Banchereau.
J Immunol, 2011 Jan 21; 186(3). PMID: 21248270    Free PMC article.
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring.
Matteo Vergati, Jeffrey Schlom, Kwong Y Tsang.
J Biomed Biotechnol, 2011 Feb 15; 2011. PMID: 21318157    Free PMC article.
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Omar S Qureshi, Yong Zheng, +12 authors, David M Sansom.
Science, 2011 Apr 09; 332(6029). PMID: 21474713    Free PMC article.
Highly Cited.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, James P Allison.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488893    Free PMC article.
Highly Cited. Review.
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
Hélène Bour-Jordan, Jonathan H Esensten, +3 authors, Jeffrey A Bluestone.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488898    Free PMC article.
Highly Cited. Review.
TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo.
Sayuri Yamazaki, Kohei Okada, +3 authors, Tsukasa Seya.
PLoS One, 2011 May 03; 6(4). PMID: 21533081    Free PMC article.
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Michael A Curran, Myoungjoo Kim, +2 authors, James P Allison.
PLoS One, 2011 May 12; 6(4). PMID: 21559358    Free PMC article.
Highly Cited.
Immunosuppressive tumor microenvironment in cervical cancer patients.
Sytse J Piersma.
Cancer Microenviron, 2011 Jun 01; 4(3). PMID: 21626415    Free PMC article.
Prostate cancer immunotherapy.
Kenneth F May, James L Gulley, +2 authors, Philip W Kantoff.
Clin Cancer Res, 2011 Jun 28; 17(16). PMID: 21700764    Free PMC article.
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner.
T Zhang, S Fresnay, +11 authors, A M Azimzadeh.
Am J Transplant, 2011 Jul 14; 11(8). PMID: 21749640    Free PMC article.
Cancer immunotherapy--revisited.
W Joost Lesterhuis, John B A G Haanen, Cornelis J A Punt.
Nat Rev Drug Discov, 2011 Aug 02; 10(8). PMID: 21804596
Highly Cited. Review.
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.
Stefanie J Mandl, Ryan B Rountree, +8 authors, Alain Delcayre.
Cancer Immunol Immunother, 2011 Aug 09; 61(1). PMID: 21822917    Free PMC article.
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Rebecca Waitz, Stephen B Solomon, +4 authors, James P Allison.
Cancer Res, 2011 Nov 24; 72(2). PMID: 22108823    Free PMC article.
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Curr Opin Immunol, 2012 Jan 13; 24(2). PMID: 22236695    Free PMC article.
Highly Cited. Review.
Immunotherapy earns its spot in the ranks of cancer therapy.
Drew Pardoll, Charles Drake.
J Exp Med, 2012 Feb 15; 209(2). PMID: 22330682    Free PMC article.
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
Serena S Kwek, Edward Cha, Lawrence Fong.
Nat Rev Cancer, 2012 Mar 02; 12(4). PMID: 22378189    Free PMC article.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Cancer immunotherapy via dendritic cells.
Karolina Palucka, Jacques Banchereau.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437871    Free PMC article.
Highly Cited. Review.
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.
Brendan Fong, Richard Jin, +6 authors, Robert M Prins.
PLoS One, 2012 Apr 10; 7(4). PMID: 22485134    Free PMC article.
Therapeutic antibodies against cancer.
Mark J Adler, Dimiter S Dimitrov.
Hematol Oncol Clin North Am, 2012 Apr 24; 26(3). PMID: 22520975    Free PMC article.
Molecular mechanisms of treg-mediated T cell suppression.
Angelika Schmidt, Nina Oberle, Peter H Krammer.
Front Immunol, 2012 May 09; 3. PMID: 22566933    Free PMC article.
Highly Cited.
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.
Florencia Paula Madorsky-Rowdo, María Laura Lacreu, José Mordoh.
Front Immunol, 2012 May 09; 3. PMID: 22566975    Free PMC article.
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Pankaj Agarwalla, Zachary Barnard, +2 authors, William T Curry.
J Immunother, 2012 May 12; 35(5). PMID: 22576343    Free PMC article.
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
Helene Pere, Corinne Tanchot, +17 authors, Eric Tartour.
Oncoimmunology, 2012 Jun 28; 1(3). PMID: 22737608    Free PMC article.
Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.
Chun Jing Wang, Rupert Kenefeck, +6 authors, Lucy S K Walker.
J Immunol, 2012 Jul 04; 189(3). PMID: 22753931    Free PMC article.
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.
Qingfei Wang, Shau-Hsuan Li, +9 authors, Dihua Yu.
Cancer Res, 2012 Jul 10; 72(17). PMID: 22773664    Free PMC article.
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.
Luis de la Cruz-Merino, Marylène Lejeune, +6 authors, Tomás Álvaro.
Clin Dev Immunol, 2012 Aug 29; 2012. PMID: 22927872    Free PMC article.
Influence of human immune cells on cancer: studies at the University of Colorado.
Tullia C Bruno, Jena D French, +7 authors, Jill E Slansky.
Immunol Res, 2012 Sep 04; 55(1-3). PMID: 22941561    Free PMC article.
From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes.
Dongmei Han, Xiaodong Cai, +2 authors, Zhibin Chen.
Front Immunol, 2012 Nov 01; 3. PMID: 23112798    Free PMC article.
Immunotherapies: the blockade of inhibitory signals.
Yan-Ling Wu, Jing Liang, +2 authors, Hiroshi Sugiyama.
Int J Biol Sci, 2012 Dec 01; 8(10). PMID: 23197939    Free PMC article.
Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity.
Amanda M Guth, Scott D Hafeman, Steven W Dow.
Oncoimmunology, 2012 Dec 18; 1(8). PMID: 23243588    Free PMC article.
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.
José I Quetglas, Liza B John, +4 authors, Cristian Smerdou.
Oncoimmunology, 2012 Dec 18; 1(8). PMID: 23243597    Free PMC article.
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer.
Harald von Boehmer, Carolin Daniel.
Nat Rev Drug Discov, 2013 Jan 01; 12(1). PMID: 23274471
Highly Cited. Review.
The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.
Melanie Stumpf, Xuyu Zhou, Jeffrey A Bluestone.
J Immunol, 2013 Jan 08; 190(3). PMID: 23293354    Free PMC article.
Advances in targeting cell surface signalling molecules for immune modulation.
Sheng Yao, Yuwen Zhu, Lieping Chen.
Nat Rev Drug Discov, 2013 Feb 02; 12(2). PMID: 23370250    Free PMC article.
Highly Cited. Review.
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Joseph F Grosso, Maria N Jure-Kunkel.
Cancer Immun, 2013 Feb 08; 13. PMID: 23390376    Free PMC article.
Highly Cited. Review.
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
C Zielinski, S Knapp, C Mascaux, F Hirsch.
Ann Oncol, 2013 Feb 09; 24(5). PMID: 23393121    Free PMC article.
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.
S A Quezada, K S Peggs.
Br J Cancer, 2013 Mar 21; 108(8). PMID: 23511566    Free PMC article.
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy.
Isabela Pedroza-Pacheco, Alejandro Madrigal, Aurore Saudemont.
Cell Mol Immunol, 2013 Mar 26; 10(3). PMID: 23524654    Free PMC article.
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
Andrew M Intlekofer, Craig B Thompson.
J Leukoc Biol, 2013 Apr 30; 94(1). PMID: 23625198    Free PMC article.
Highly Cited. Review.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy, Karen M Kaluza, Gordon J Freeman, George Coukos.
Cancer Res, 2013 May 02; 73(12). PMID: 23633484    Free PMC article.
Highly Cited.
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Stefania Laurent, Paola Queirolo, +15 authors, Maria Pia Pistillo.
J Transl Med, 2013 May 03; 11. PMID: 23634660    Free PMC article.
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.
Bartosz Chmielowski.
J Skin Cancer, 2013 Jun 06; 2013. PMID: 23738073    Free PMC article.
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.
Vincent Lavoué, Aurélie Thédrez, +6 authors, Florian Cabillic.
J Transl Med, 2013 Jun 15; 11. PMID: 23763830    Free PMC article.
Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
Chunrui Tan, Varun Reddy, +5 authors, Walter T Lee.
J Transl Med, 2013 Jun 19; 11. PMID: 23768240    Free PMC article.
Suppression of acute graft-versus-host response by TCDD is independent of the CTLA-4-IFN-γ-IDO pathway.
Diana Rohlman, Sumit Punj, +2 authors, Nancy I Kerkvliet.
Toxicol Sci, 2013 Jun 27; 135(1). PMID: 23798565    Free PMC article.
Immunosuppressive microenvironment in neuroblastoma.
Vito Pistoia, Fabio Morandi, +3 authors, Lizzia Raffaghello.
Front Oncol, 2013 Jun 28; 3. PMID: 23805414    Free PMC article.
Treg and CTLA-4: two intertwining pathways to immune tolerance.
Lucy S K Walker.
J Autoimmun, 2013 Jul 16; 45. PMID: 23849743    Free PMC article.
Highly Cited. Review.
New insights into the role of the immune microenvironment in breast carcinoma.
Luis de la Cruz-Merino, Antonio Barco-Sánchez, +12 authors, José Ibáñez Martínez.
Clin Dev Immunol, 2013 Jul 19; 2013. PMID: 23861693    Free PMC article.
Dendritic-cell-based therapeutic cancer vaccines.
Karolina Palucka, Jacques Banchereau.
Immunity, 2013 Jul 31; 39(1). PMID: 23890062    Free PMC article.
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Promising systemic immunotherapies in head and neck squamous cell carcinoma.
Neil Gildener-Leapman, Robert L Ferris, Julie E Bauman.
Oral Oncol, 2013 Oct 16; 49(12). PMID: 24126223    Free PMC article.
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.
Paula D Bos, George Plitas, +2 authors, Alexander Y Rudensky.
J Exp Med, 2013 Oct 16; 210(11). PMID: 24127486    Free PMC article.
Highly Cited.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Update on vaccine development for renal cell cancer.
Nina Chi, Jodi K Maranchie, Leonard J Appleman, Walter J Storkus.
Open Access J Urol, 2010 Jan 01; 2. PMID: 24198621    Free PMC article.
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.
Giulio Tosti, Emilia Cocorocchio, Elisabetta Pennacchioli.
Clin Cosmet Investig Dermatol, 2013 Nov 10; 6. PMID: 24204168    Free PMC article.
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.
Genevieve M Weir, Robert S Liwski, Marc Mansour.
Cancers (Basel), 2011 Jan 01; 3(3). PMID: 24212948    Free PMC article.
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Julie E Bauman, Robert L Ferris.
Cancer, 2013 Nov 14; 120(5). PMID: 24222079    Free PMC article.
Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.
Simone P Sittig, Tania Køllgaard, +5 authors, Per Thor Straten.
Oncoimmunology, 2013 Nov 15; 2(9). PMID: 24228230    Free PMC article.
Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells.
Birgit Tsaknakis, Inga-Marie Schaefer, +5 authors, Silke Cameron.
Med Oncol, 2013 Dec 18; 31(1). PMID: 24338272
Tumor immunology: multidisciplinary science driving basic and clinical advances.
Bridget P Keenan, Elizabeth M Jaffee, Todd D Armstrong.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409447    Free PMC article.
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
Margaret K Callahan, Gregg Masters, +13 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 15; 2(1). PMID: 24416731    Free PMC article.
Development of anticancer drugs based on the hallmarks of tumor cells.
Natalia Bailón-Moscoso, Juan Carlos Romero-Benavides, Patricia Ostrosky-Wegman.
Tumour Biol, 2014 Jan 29; 35(5). PMID: 24470139
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Lucia Gelao, Carmen Criscitiello, +2 authors, Giuseppe Curigliano.
Toxins (Basel), 2014 Mar 07; 6(3). PMID: 24594636    Free PMC article.
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Raffaella Iannone, Lucio Miele, +2 authors, Silvana Morello.
Am J Cancer Res, 2014 Mar 25; 4(2). PMID: 24660106    Free PMC article.
Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model.
Yuya Yoshimoto, Yoshiyuki Suzuki, +10 authors, Takashi Nakano.
PLoS One, 2014 Apr 02; 9(3). PMID: 24686897    Free PMC article.
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C Sandin, Fredrik Eriksson, +3 authors, Sara M Mangsbo.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701377    Free PMC article.
Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.
Kok-Fai Kong, Guo Fu, +10 authors, Amnon Altman.
Nat Immunol, 2014 Apr 08; 15(5). PMID: 24705298    Free PMC article.
Highly Cited.
Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia.
D Saulep-Easton, F B Vincent, +5 authors, F Mackay.
Leukemia, 2014 Apr 12; 28(10). PMID: 24721775    Free PMC article.
Pathways and therapeutic targets in melanoma.
Emma Shtivelman, Michael Q A Davies, +5 authors, David E Fisher.
Oncotarget, 2014 Apr 20; 5(7). PMID: 24743024    Free PMC article.
Highly Cited. Review.
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
Thomas E Stinchcombe.
Med Oncol, 2014 Apr 22; 31(5). PMID: 24748366    Free PMC article.
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778278    Free PMC article.
What have we learned from cancer immunotherapy in the last 3 years?
Paolo A Ascierto, Francesco M Marincola.
J Transl Med, 2014 Jun 03; 12. PMID: 24886164    Free PMC article.
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Andreas Herrmann, Saul J Priceman, +10 authors, Hua Yu.
J Clin Invest, 2014 Jun 04; 124(7). PMID: 24892807    Free PMC article.
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Tai Hato, Lipika Goyal, +2 authors, Andrew X Zhu.
Hepatology, 2014 Jun 11; 60(5). PMID: 24912948    Free PMC article.
Highly Cited. Review.
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Delia Nelson, Scott Fisher, Bruce Robinson.
J Immunol Res, 2014 Jun 24; 2014. PMID: 24955376    Free PMC article.
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).
Sadek Malas, Micaela Harrasser, Katie E Lacy, Sophia N Karagiannis.
Oncol Rep, 2014 Jun 28; 32(3). PMID: 24969320    Free PMC article.
An updated overview of HPV-associated head and neck carcinomas.
Apostolos Zaravinos.
Oncotarget, 2014 Jun 28; 5(12). PMID: 24970795    Free PMC article.
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Sheetal Bodhankar, Yingxin Chen, +3 authors, Halina Offner.
Front Cell Neurosci, 2014 Aug 27; 8. PMID: 25157219    Free PMC article.
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.
Scott A Fisher, Amanda Cleaver, +6 authors, Richard A Lake.
J Transl Med, 2014 Sep 05; 12. PMID: 25186961    Free PMC article.
Immunotherapy advances for glioblastoma.
David A Reardon, Gordon Freeman, +7 authors, Glenn Dranoff.
Neuro Oncol, 2014 Sep 06; 16(11). PMID: 25190673    Free PMC article.
Highly Cited. Review.
Clinical cancer research: the past, present and the future.
Vincent T DeVita, Alexander M M Eggermont, Samuel Hellman, David J Kerr.
Nat Rev Clin Oncol, 2014 Sep 24; 11(11). PMID: 25245981
Targeting regulatory T cells to improve vaccine immunogenicity in early life.
Jorjoh Ndure, Katie L Flanagan.
Front Microbiol, 2014 Oct 14; 5. PMID: 25309517    Free PMC article.
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Kristina M Ilieva, Isabel Correa, +8 authors, Sophia N Karagiannis.
Mol Cancer Ther, 2014 Nov 12; 13(12). PMID: 25385327    Free PMC article.
Immunotherapy for primary brain tumors: no longer a matter of privilege.
Peter E Fecci, Amy B Heimberger, John H Sampson.
Clin Cancer Res, 2014 Nov 16; 20(22). PMID: 25398845    Free PMC article.
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.
Michael R Olin, G Elizabeth Pluhar, +3 authors, Christopher L Moertel.
Crit Rev Immunol, 2014 Nov 19; 34(5). PMID: 25404047    Free PMC article.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Chemokines in cancer.
Melvyn T Chow, Andrew D Luster.
Cancer Immunol Res, 2014 Dec 07; 2(12). PMID: 25480554    Free PMC article.
Highly Cited. Review.
Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.
Duane Moogk, Ines Pires da Silva, +10 authors, Michelle Krogsgaard.
J Transl Med, 2014 Dec 11; 12. PMID: 25491880    Free PMC article.
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.
Timothy J Haggerty, Ian S Dunn, +3 authors, James T Kurnick.
PLoS One, 2014 Dec 17; 9(12). PMID: 25503774    Free PMC article.
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Linh T Nguyen, Pamela S Ohashi.
Nat Rev Immunol, 2014 Dec 24; 15(1). PMID: 25534622
Highly Cited. Review.
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Dalil Hannani, Marie Vétizou, +30 authors, Laurence Zitvogel.
Cell Res, 2015 Jan 15; 25(2). PMID: 25582080    Free PMC article.
Highly Cited.
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Weiqing Jing, Jill A Gershan, +4 authors, Bryon D Johnson.
J Immunother Cancer, 2015 Jan 24; 3(1). PMID: 25614821    Free PMC article.
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Jason J Luke, Patrick A Ott.
Oncotarget, 2015 Feb 17; 6(6). PMID: 25682878    Free PMC article.
Highly Cited. Review.
Immunotherapeutic advancements for glioblastoma.
Leonel Ampie, Eric C Woolf, Christopher Dardis.
Front Oncol, 2015 Feb 18; 5. PMID: 25688335    Free PMC article.
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond.
Front Oncol, 2015 Mar 13; 5. PMID: 25763356    Free PMC article.
Highly Cited. Review.
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
Maria Napolitano, Crescenzo D'Alterio, +11 authors, Stefania Scala.
Oncotarget, 2015 Apr 01; 6(10). PMID: 25823653    Free PMC article.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Victoria Hillerdal, Magnus Essand.
BioDrugs, 2015 Apr 11; 29(2). PMID: 25859858    Free PMC article.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Mechanisms of action of therapeutic antibodies for cancer.
J M Redman, E M Hill, D AlDeghaither, L M Weiner.
Mol Immunol, 2015 Apr 29; 67(2 Pt A). PMID: 25911943    Free PMC article.
Regulatory T cells turn pathogenic.
Jitao Guo, Xuyu Zhou.
Cell Mol Immunol, 2015 May 06; 12(5). PMID: 25942597    Free PMC article.
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.
A Doran Bostwick, April K Salama, Brent A Hanks.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992290    Free PMC article.
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992292    Free PMC article.
Highly Cited.
Beyond adjuvants: immunomodulation strategies to enhance T cell immunity.
Alice O Kamphorst, Koichi Araki, Rafi Ahmed.
Vaccine, 2015 May 30; 33 Suppl 2. PMID: 26022562    Free PMC article.
Predictive biomarkers in precision medicine and drug development against lung cancer.
Bingliang Fang, Reza J Mehran, John V Heymach, Stephen G Swisher.
Chin J Cancer, 2015 Jul 03; 34(7). PMID: 26134262    Free PMC article.
Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.
Louisa E Jeffery, Omar S Qureshi, +6 authors, David M Sansom.
PLoS One, 2015 Jul 03; 10(7). PMID: 26134669    Free PMC article.
Clinical Development of Immune Checkpoint Inhibitors.
Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano.
Biomed Res Int, 2015 Jul 15; 2015. PMID: 26161407    Free PMC article.
Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies.
Lu Wang, Zhiwei Jiang, +3 authors, Lixin Wang.
Int J Clin Exp Med, 2015 Jul 30; 8(5). PMID: 26221222    Free PMC article.
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
Francesca De Felice, Claudia Marchetti, +4 authors, Pierluigi Benedetti Panici.
J Immunol Res, 2015 Aug 04; 2015. PMID: 26236750    Free PMC article.
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
Simon Ville, Nicolas Poirier, Gilles Blancho, Bernard Vanhove.
Front Immunol, 2015 Sep 01; 6. PMID: 26322044    Free PMC article.
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Elizabeth Buchbinder, F Stephen Hodi.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325034    Free PMC article.
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.
Giorgio Parmiani, Cristina Maccalli, Michele Maio.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343195    Free PMC article.
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.
Wendy Wj Unger, Christian T Mayer, +9 authors, Yvette van Kooyk.
Oncoimmunology, 2015 Sep 26; 4(8). PMID: 26405564    Free PMC article.
Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Alan Serrels, Tom Lund, +15 authors, Margaret C Frame.
Cell, 2015 Sep 26; 163(1). PMID: 26406376    Free PMC article.
Highly Cited.
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
N Yamazaki, H Uhara, +8 authors, T Tokudome.
Cancer Chemother Pharmacol, 2015 Sep 27; 76(5). PMID: 26407818    Free PMC article.
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
N Yamazaki, Y Kiyohara, +8 authors, T Tokudome.
Cancer Chemother Pharmacol, 2015 Sep 28; 76(5). PMID: 26410424    Free PMC article.
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro.
Nat Rev Gastroenterol Hepatol, 2015 Oct 21; 12(12). PMID: 26484443
Highly Cited. Review.
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.
Alexander G Raufi, Samuel J Klempner.
J Gastrointest Oncol, 2015 Oct 22; 6(5). PMID: 26487950    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.
Kelly Kersten, Camilla Salvagno, Karin E de Visser.
Front Immunol, 2015 Oct 27; 6. PMID: 26500653    Free PMC article.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.
Anna Śledzińska, Laurie Menger, +2 authors, Sergio A Quezada.
Mol Oncol, 2015 Nov 19; 9(10). PMID: 26578451    Free PMC article.
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Karishma R Rajani, Richard G Vile.
Viruses, 2015 Nov 19; 7(11). PMID: 26580645    Free PMC article.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer.
M J McCoy, C Hemmings, +6 authors, C F Platell.
Br J Cancer, 2015 Dec 10; 113(12). PMID: 26645238    Free PMC article.
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.
Omar A Ali, Sarah A Lewin, Glenn Dranoff, David J Mooney.
Cancer Immunol Res, 2015 Dec 17; 4(2). PMID: 26669718    Free PMC article.
Translating Treg Therapy in Humanized Mice.
Susanne A Hahn, Iris Bellinghausen, Bettina Trinschek, Christian Becker.
Front Immunol, 2015 Dec 24; 6. PMID: 26697017    Free PMC article.
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Stefanie N Linch, Melissa J Kasiewicz, +3 authors, William L Redmond.
Proc Natl Acad Sci U S A, 2016 Jan 06; 113(3). PMID: 26729864    Free PMC article.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Tai Hato, Andrew X Zhu, Dan G Duda.
Immunotherapy, 2016 Feb 13; 8(3). PMID: 26865127    Free PMC article.
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Paola Savoia, Chiara Astrua, Paolo Fava.
Hum Vaccin Immunother, 2016 Feb 19; 12(5). PMID: 26889818    Free PMC article.
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Angela K B Alme, Beerinder S Karir, Bishoy M Faltas, Charles G Drake.
Urol Oncol, 2016 Mar 01; 34(4). PMID: 26923782    Free PMC article.
Targeting metastasis.
Patricia S Steeg.
Nat Rev Cancer, 2016 Mar 25; 16(4). PMID: 27009393    Free PMC article.
Highly Cited. Review.
Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis.
Xiao-Fei Zhang, Ke Pan, +9 authors, Jian-Chuan Xia.
Oncotarget, 2016 Apr 07; 7(18). PMID: 27050369    Free PMC article.
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
Cristina Maccalli, Diana Giannarelli, +5 authors, Michele Maio.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057436    Free PMC article.
Emerging therapeutic targets in esophageal adenocarcinoma.
Puja Gaur, Clayton R Hunt, Tej K Pandita.
Oncotarget, 2016 Apr 23; 7(30). PMID: 27102294    Free PMC article.
Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis.
Yan-Qing Yang, Wei Yang, +6 authors, Zhe-Xiong Lian.
Oncotarget, 2016 Apr 23; 7(19). PMID: 27105495    Free PMC article.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, +14 authors, Caroline Robert.
Nat Rev Clin Oncol, 2016 May 05; 13(8). PMID: 27141885
Highly Cited. Review.
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.
Ryan Montler, R Bryan Bell, +8 authors, Andrew Weinberg.
Clin Transl Immunology, 2016 May 20; 5(4). PMID: 27195113    Free PMC article.
Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression.
Jacobo López-Abente, Rafael Correa-Rocha, Marjorie Pion.
Front Immunol, 2016 Jun 01; 7. PMID: 27242797    Free PMC article.
Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity.
Hajime Kashima, Fumiyasu Momose, +6 authors, Akira Asai.
PLoS One, 2016 Jun 11; 11(6). PMID: 27284967    Free PMC article.
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy.
Stefanie N Linch, William L Redmond.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330804    Free PMC article.
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.
Janet Retseck, Robert VanderWeele, +3 authors, Ahmad A Tarhini.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330811    Free PMC article.
Recent advances and future of immunotherapy for glioblastoma.
Neha Kamran, Alexandra Calinescu, +7 authors, Maria G Castro.
Expert Opin Biol Ther, 2016 Jul 14; 16(10). PMID: 27411023    Free PMC article.
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.
Marwa Matboli, Sarah El-Nakeep, +5 authors, Omar Abdel-Rahman.
World J Gastroenterol, 2016 Jul 29; 22(26). PMID: 27468184    Free PMC article.
Prioritization schema for immunotherapy clinical trials in glioblastoma.
Tiffany R Hodges, Sherise D Ferguson, +17 authors, Amy B Heimberger.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471611    Free PMC article.
Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.
E C Halvorsen, M J Hamilton, +6 authors, K L Bennewith.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471618    Free PMC article.
Cancer testis antigen and immunotherapy.
Deepa Kolaseri Krishnadas, Fanqi Bai, Kenneth G Lucas.
Immunotargets Ther, 2013 Jan 01; 2. PMID: 27471684    Free PMC article.
Immunotherapy in genitourinary malignancies.
Max M Wattenberg, Lawrence Fong, Ravi A Madan, James L Gulley.
Curr Opin Urol, 2016 Jul 30; 26(6). PMID: 27471994    Free PMC article.
Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
David Gill, Andrew W Hahn, Guru Sonpavde, Neeraj Agarwal.
Hum Vaccin Immunother, 2016 Aug 06; 12(12). PMID: 27494417    Free PMC article.
Regulatory circuits of T cell function in cancer.
Daniel E Speiser, Ping-Chih Ho, Grégory Verdeil.
Nat Rev Immunol, 2016 Aug 17; 16(10). PMID: 27526640
Highly Cited. Review.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity.
Yang-Zhuo Gu, Chuan-Wen Fan, +7 authors, Yu-Quan Wei.
Sci Rep, 2016 Aug 31; 6. PMID: 27571893    Free PMC article.
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?
Pavan Patel, Steven E Schutzer, Nikolaos Pyrsopoulos.
World J Gastrointest Pathophysiol, 2016 Aug 31; 7(3). PMID: 27574562    Free PMC article.
Immunotherapy for Gastroesophageal Cancer.
Emily F Goode, Elizabeth C Smyth.
J Clin Med, 2016 Sep 27; 5(10). PMID: 27669318    Free PMC article.
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.
Zhaohui Jin, Harry H Yoon.
J Gastrointest Oncol, 2016 Oct 18; 7(5). PMID: 27747091    Free PMC article.
Targeting immune checkpoints in malignant glioma.
Xuhao Zhang, Shan Zhu, +3 authors, Jingtao Chen.
Oncotarget, 2016 Oct 21; 8(4). PMID: 27756892    Free PMC article.
The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal, Yasin Şenbabaoğlu, +8 authors, Luc Gt Morris.
JCI Insight, 2016 Oct 26; 1(17). PMID: 27777979    Free PMC article.
Highly Cited.
Recent advances in understanding antitumor immunity.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
F1000Res, 2016 Nov 03; 5. PMID: 27803807    Free PMC article.
Combinatorial immunotherapy for melanoma.
D D George, V A Armenio, S C Katz.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834353
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
Eric K Ring, James M Markert, G Yancey Gillespie, Gregory K Friedman.
Clin Cancer Res, 2016 Nov 12; 23(2). PMID: 27836863    Free PMC article.
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Maarten Swart, Inge Verbrugge, Joost B Beltman.
Front Oncol, 2016 Nov 17; 6. PMID: 27847783    Free PMC article.
Highly Cited. Review.
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.
Marco De Simone, Alberto Arrigoni, +28 authors, Massimiliano Pagani.
Immunity, 2016 Nov 17; 45(5). PMID: 27851914    Free PMC article.
Highly Cited.
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma.
Walid L Shaib, Jean Paul A Nammour, +2 authors, Nabil F Saba.
J Clin Med, 2016 Nov 18; 5(11). PMID: 27854242    Free PMC article.
T-cell programming in pancreatic adenocarcinoma: a review.
Y D Seo, V G Pillarisetty.
Cancer Gene Ther, 2016 Dec 03; 24(3). PMID: 27910859
Immune checkpoint therapy for pancreatic cancer.
Henrik Johansson, Roland Andersson, +3 authors, Daniel Ansari.
World J Gastroenterol, 2016 Dec 07; 22(43). PMID: 27920468    Free PMC article.
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.
Jae Hyuck Chang, Yongjian Jiang, Venu G Pillarisetty.
Medicine (Baltimore), 2016 Dec 09; 95(49). PMID: 27930550    Free PMC article.
The Safety of available immunotherapy for the treatment of glioblastoma.
S Harrison Farber, Aladine A Elsamadicy, +4 authors, John H Sampson.
Expert Opin Drug Saf, 2016 Dec 19; 16(3). PMID: 27989218    Free PMC article.
Reprogramming the immunological microenvironment through radiation and targeting Axl.
Todd A Aguilera, Marjan Rafat, +12 authors, Amato J Giaccia.
Nat Commun, 2016 Dec 23; 7. PMID: 28008921    Free PMC article.
Highly Cited.
A New VISTA on combination therapy for negative checkpoint regulator blockade.
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J Noelle.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031817    Free PMC article.
TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis.
Michael P Holt, George A Punkosdy, Deborah D Glass, Ethan M Shevach.
J Immunol, 2017 Jan 06; 198(4). PMID: 28053234    Free PMC article.
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger.
Cell Commun Signal, 2017 Jan 12; 15(1). PMID: 28073373    Free PMC article.
Highly Cited. Review.
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Franck Carbonnel, Emilie Soularue, +4 authors, Caroline Robert.
Semin Immunopathol, 2017 Jan 18; 39(3). PMID: 28093620
Tumor regulation of the tissue environment in the liver.
Tobias Eggert, Tim F Greten.
Pharmacol Ther, 2017 Feb 09; 173. PMID: 28167218    Free PMC article.
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
Kilian Wistuba-Hamprecht, Alexander Martens, +18 authors, Benjamin Weide.
Eur J Cancer, 2017 Feb 09; 73. PMID: 28167454    Free PMC article.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
Targeting PD-1/PD-L1 in lung cancer: current perspectives.
María González-Cao, Niki Karachaliou, +6 authors, Rafael Rosell.
Lung Cancer (Auckl), 2015 Jul 31; 6. PMID: 28210151    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Immunotherapy in pancreatic cancer treatment: a new frontier.
Komal Thind, Leslie J Padrnos, Ramesh K Ramanathan, Mitesh J Borad.
Therap Adv Gastroenterol, 2017 Mar 14; 10(1). PMID: 28286568    Free PMC article.
Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
Wiktoria Blaszczak, Wojciech Barczak, +2 authors, Wiktoria Maria Suchorska.
Med Oncol, 2017 Mar 21; 34(4). PMID: 28315228    Free PMC article.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Randy F Sweis, Jason J Luke.
Pharmacol Res, 2017 Mar 23; 120. PMID: 28323141    Free PMC article.
CAR T-cell therapy for pancreatic cancer.
Carl J DeSelm, Zachary E Tano, Anna M Varghese, Prasad S Adusumilli.
J Surg Oncol, 2017 Mar 28; 116(1). PMID: 28346697    Free PMC article.
Cancer Immunotherapy: Whence and Whither.
Peter J Stambrook, John Maher, Farzin Farzaneh.
Mol Cancer Res, 2017 Mar 31; 15(6). PMID: 28356330    Free PMC article.
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.
Ornella Franzese, Francesco Torino, +5 authors, Stefania D'Atri.
Oncotarget, 2017 Apr 14; 8(25). PMID: 28404974    Free PMC article.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Frederick Arce Vargas, Andrew J S Furness, +29 authors, Sergio A Quezada.
Immunity, 2017 Apr 16; 46(4). PMID: 28410988    Free PMC article.
Highly Cited.
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Jon Bjoern, Rikke Lyngaa, +4 authors, Inge Marie Svane.
Oncotarget, 2017 Apr 21; 8(16). PMID: 28423678    Free PMC article.
Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
David M Francis, Susan N Thomas.
Adv Drug Deliv Rev, 2017 Apr 30; 114. PMID: 28455187    Free PMC article.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt.
Drugs, 2017 May 12; 77(10). PMID: 28493171
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Upendra P Hegde, Bijay Mukherji.
Cancer Immunol Immunother, 2017 May 13; 66(9). PMID: 28497159    Free PMC article.
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Jessica M Moskovitz, Jennifer Moy, Tanguy Y Seiwert, Robert L Ferris.
Oncologist, 2017 May 17; 22(6). PMID: 28507203    Free PMC article.
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.
Fade Mahmoud, Bradley Shields, +5 authors, Alan J Tackett.
Cancer Biol Ther, 2017 May 18; 18(7). PMID: 28513269    Free PMC article.
Current state of immunotherapy for non-small cell lung cancer.
Jyoti Malhotra, Salma K Jabbour, Joseph Aisner.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529902    Free PMC article.
Highly Cited. Review.
Melanoma: tumor microenvironment and new treatments.
Mara Huffenbaecher Giavina-Bianchi, Pedro Francisco Giavina-Bianchi, Cyro Festa.
An Bras Dermatol, 2017 May 26; 92(2). PMID: 28538872    Free PMC article.
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Jingyu Zhang, Dai Liu, +4 authors, Jennifer D Wu.
Sci Adv, 2017 Jun 01; 3(5). PMID: 28560327    Free PMC article.
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition.
Sebastian Peer, Gottfried Baier, Thomas Gruber.
Oncotarget, 2017 Jun 15; 8(26). PMID: 28611299    Free PMC article.
Molecular imaging biomarkers for cell-based immunotherapies.
Mohammad Haris, Puneet Bagga, +3 authors, Ravinder Reddy.
J Transl Med, 2017 Jun 21; 15(1). PMID: 28629457    Free PMC article.
CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation.
Holger Lingel, Josef Wissing, +7 authors, Monika C Brunner-Weinzierl.
Cell Death Differ, 2017 Jun 24; 24(10). PMID: 28644433    Free PMC article.
Negative Correlation between Circulating CD4+FOXP3+CD127- Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role.
Jorjoh Ndure, Fatou Noho-Konteh, +10 authors, Katie L Flanagan.
Front Immunol, 2017 Sep 01; 8. PMID: 28855899    Free PMC article.
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
Margaret E Gatti-Mays, Jason M Redman, Julie M Collins, Marijo Bilusic.
Hum Vaccin Immunother, 2017 Sep 01; 13(11). PMID: 28857666    Free PMC article.
EMT and Treatment Resistance in Pancreatic Cancer.
Nicola Gaianigo, Davide Melisi, Carmine Carbone.
Cancers (Basel), 2017 Sep 13; 9(9). PMID: 28895920    Free PMC article.
Highly Cited. Review.
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.
Benjamin A Kansy, Fernando Concha-Benavente, +13 authors, Robert L Ferris.
Cancer Res, 2017 Sep 15; 77(22). PMID: 28904066    Free PMC article.
Highly Cited.
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.
Paul E Clavijo, Ellen C Moore, +6 authors, Clint T Allen.
Oncotarget, 2017 Sep 17; 8(34). PMID: 28915554    Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.
Eric K Ring, Rong Li, +8 authors, Gregory K Friedman.
Mol Ther Oncolytics, 2017 Oct 17; 7. PMID: 29034313    Free PMC article.
The immune system in cancer metastasis: friend or foe?
Louise M E Janssen, Emma E Ramsay, Craig D Logsdon, Willem W Overwijk.
J Immunother Cancer, 2017 Oct 19; 5(1). PMID: 29037250    Free PMC article.
Highly Cited. Review.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Russell W Jenkins, Amir R Aref, +81 authors, David A Barbie.
Cancer Discov, 2017 Nov 05; 8(2). PMID: 29101162    Free PMC article.
Highly Cited.
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul J Carter, Greg A Lazar.
Nat Rev Drug Discov, 2017 Dec 02; 17(3). PMID: 29192287
Highly Cited. Review.
Screening and antitumor effect of an anti‑CTLA‑4 nanobody.
Ruirong Wan, Aiqun Liu, +9 authors, Xiaoling Lu.
Oncol Rep, 2017 Dec 06; 39(2). PMID: 29207143    Free PMC article.
Tregs: Where We Are and What Comes Next?
Hai Zhao, Xuelian Liao, Yan Kang.
Front Immunol, 2017 Dec 12; 8. PMID: 29225597    Free PMC article.
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models.
Katherine E Lewis, Mark J Selby, +11 authors, Stacey R Dillon.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296539    Free PMC article.
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.
Neus Martinez-Bosch, Judith Vinaixa, Pilar Navarro.
Cancers (Basel), 2018 Jan 06; 10(1). PMID: 29301364    Free PMC article.
Highly Cited. Review.
Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression.
Hayana Ramos Lima, Thaís Helena Gasparoto, +10 authors, Ana Paula Campanelli.
Front Immunol, 2018 Jan 10; 8. PMID: 29312289    Free PMC article.
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.
Joseph R Podojil, Iris Hecht, +6 authors, Stephen D Miller.
J Immunol, 2018 Feb 13; 200(6). PMID: 29431690    Free PMC article.
Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.
Megan Morisada, Michael Chamberlin, Clint Allen.
Head Neck, 2018 Feb 21; 40(6). PMID: 29461655    Free PMC article.
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.
Rajani Ravi, Kimberly A Noonan, +13 authors, Atul Bedi.
Nat Commun, 2018 Feb 23; 9(1). PMID: 29467463    Free PMC article.
Highly Cited.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Antje Tunger, Maximilian Kießler, +4 authors, Marc Schmitz.
Biomedicines, 2018 Mar 02; 6(1). PMID: 29494517    Free PMC article.
Checks and Balances in Autoimmune Vasculitis.
Rebeca Hid Cadena, Wayel H Abdulahad, +4 authors, Elisabeth Brouwer.
Front Immunol, 2018 Mar 10; 9. PMID: 29520282    Free PMC article.
Current Strategies to Enhance Anti-Tumour Immunity.
Katherine W Cook, Lindy G Durrant, Victoria A Brentville.
Biomedicines, 2018 Mar 24; 6(2). PMID: 29570634    Free PMC article.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Benoît L Salomon, Mathieu Leclerc, +3 authors, José L Cohen.
Front Immunol, 2018 Mar 30; 9. PMID: 29593717    Free PMC article.
Novel Systemic Therapies for Advanced Gastric Cancer.
Hong Jun Kim, Sang Cheul Oh.
J Gastric Cancer, 2018 Apr 10; 18(1). PMID: 29629216    Free PMC article.
The opposing roles of CD4+ T cells in anti-tumour immunity.
Tomasz Ahrends, Jannie Borst.
Immunology, 2018 Apr 28;. PMID: 29700809    Free PMC article.
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, +7 authors, Patrick J Stiff.
J Ovarian Res, 2018 May 31; 11(1). PMID: 29843813    Free PMC article.
CNS cancer immunity cycle and strategies to target this for glioblastoma.
Malaka Ameratunga, Niamh Coleman, +2 authors, Juanita Lopez.
Oncotarget, 2018 Jun 02; 9(32). PMID: 29854316    Free PMC article.
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
Christian M Schürch.
Front Oncol, 2018 Jun 06; 8. PMID: 29868474    Free PMC article.
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Elizabeth Ahern, Heidi Harjunpää, +4 authors, Mark J Smyth.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872559    Free PMC article.
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
Dharmesh Gopalakrishnan, Vadim S Koshkin, +2 authors, Petros Grivas.
Ther Clin Risk Manag, 2018 Jun 13; 14. PMID: 29892196    Free PMC article.
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Skyler B Johnson, James B Yu.
Curr Oncol Rep, 2018 Jul 01; 20(9). PMID: 29959582
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Abigail E Overacre-Delgoffe, Dario A A Vignali.
Cancer Immunol Res, 2018 Aug 03; 6(8). PMID: 30068755    Free PMC article.
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.
Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122997    Free PMC article.
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Derya Kabacaoglu, Katrin J Ciecielski, Dietrich A Ruess, Hana Algül.
Front Immunol, 2018 Aug 31; 9. PMID: 30158932    Free PMC article.
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Prabhakaran Kumar, Palash Bhattacharya, Bellur S Prabhakar.
J Autoimmun, 2018 Sep 04; 95. PMID: 30174217    Free PMC article.
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Lee-Shing Chang, Romualdo Barroso-Sousa, +3 authors, Le Min.
Endocr Rev, 2018 Sep 06; 40(1). PMID: 30184160    Free PMC article.
Immune checkpoint inhibitors for hepatocellular carcinoma.
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes.
Hepat Oncol, 2016 Aug 01; 3(3). PMID: 30191042    Free PMC article.
New developments in immunotherapy for lymphoma.
Benjamin Heyman, Yiping Yang.
Cancer Biol Med, 2018 Sep 11; 15(3). PMID: 30197788    Free PMC article.
Regulatory T cells in the treatment of disease.
Amir Sharabi, Maria G Tsokos, +3 authors, George C Tsokos.
Nat Rev Drug Discov, 2018 Oct 13; 17(11). PMID: 30310234
Highly Cited. Review.
Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Federica Costa, Rituparna Das, +2 authors, Madhav V Dhodapkar.
Front Immunol, 2018 Oct 16; 9. PMID: 30319648    Free PMC article.
Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.
Angela M Magnuson, Evgeny Kiner, +8 authors, Christophe Benoist.
Proc Natl Acad Sci U S A, 2018 Oct 24; 115(45). PMID: 30348759    Free PMC article.
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Kyung-Ann Lee, Hae-Rim Kim, So Young Yoon.
Korean J Intern Med, 2019 Apr 25; 34(6). PMID: 31014065    Free PMC article.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.
Daniel P Hollern, Nuo Xu, +15 authors, Charles M Perou.
Cell, 2019 Nov 16; 179(5). PMID: 31730857    Free PMC article.
Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions.
Albert J Czaja.
World J Gastroenterol, 2019 Dec 14; 25(45). PMID: 31832000    Free PMC article.
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
Yu-Wen Zhou, Ya-Juan Zhu, +6 authors, Ji-Yan Liu.
Front Pharmacol, 2019 Dec 19; 10. PMID: 31849640    Free PMC article.
Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model.
Qian Zhuo, Bohai Yu, +5 authors, Shuli Zhao.
Sci Rep, 2019 Dec 29; 9(1). PMID: 31882868    Free PMC article.
The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
Kroopa Joshi, Benjamin M Chain, Karl S Peggs, Sergio A Quezada.
Cold Spring Harb Perspect Med, 2017 Jun 21; 8(1). PMID: 28630228    Free PMC article.
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Fa-Peng Zhang, Yi-Pei Huang, +4 authors, Chao Liu.
World J Gastroenterol, 2020 Jan 24; 26(2). PMID: 31969776    Free PMC article.
Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.
Neeha Zaidi, Sergio A Quezada, +4 authors, Bei Wang.
Ann N Y Acad Sci, 2019 Apr 05; 1445(1). PMID: 30945313    Free PMC article.
An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.
Suresh Veeramani, Sue E Blackwell, +4 authors, George J Weiner.
Cancer Immunol Res, 2019 Aug 07; 7(9). PMID: 31383650    Free PMC article.
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.
Naveen Sharma, Jean Vacher, James P Allison.
Proc Natl Acad Sci U S A, 2019 May 12; 116(21). PMID: 31076558    Free PMC article.
CTLA-4: a moving target in immunotherapy.
Behzad Rowshanravan, Neil Halliday, David M Sansom.
Blood, 2017 Nov 10; 131(1). PMID: 29118008    Free PMC article.
Highly Cited. Review.
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han.
J Hematol Oncol, 2018 Feb 28; 11(1). PMID: 29482595    Free PMC article.
Highly Cited. Review.
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Ariel E Marciscano, Ali Ghasemzadeh, +18 authors, Charles G Drake.
Clin Cancer Res, 2018 Jun 15; 24(20). PMID: 29898992    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Huijun Zhang, Pranabananda Dutta, +4 authors, Jinghong Li.
J Cell Mol Med, 2018 Nov 01; 23(1). PMID: 30378264    Free PMC article.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Chien-Chun Steven Pai, Donald M Simons, +22 authors, Lawrence Fong.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530991    Free PMC article.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Alexandros Papachristofilou, Madeleine M Hipp, +24 authors, Alfred Zippelius.
J Immunother Cancer, 2019 Feb 10; 7(1). PMID: 30736848    Free PMC article.
Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells.
Yuxuan Miao, Hanseul Yang, +6 authors, Elaine Fuchs.
Cell, 2019 Apr 30; 177(5). PMID: 31031009    Free PMC article.
Highly Cited.
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Hiroshi Yano, Lawrence P Andrews, Creg J Workman, Dario A A Vignali.
Immunology, 2019 May 16; 157(3). PMID: 31087644    Free PMC article.
Highly Cited. Review.
Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy.
James Sun, Dennis A Kirichenko, +8 authors, Sephalie Y Patel.
World J Surg, 2019 Dec 08; 44(4). PMID: 31811340
An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.
Jialing Zhang, Stephan S Späth, Sherman M Weissman, Samuel G Katz.
Methods Mol Biol, 2019 Nov 30; 2097. PMID: 31776925    Free PMC article.
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy.
Ioana Plesca, Antje Tunger, +6 authors, Marc Schmitz.
Front Immunol, 2020 Mar 21; 11. PMID: 32194568    Free PMC article.
Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
Francesca Arruga, Benjamin Baffour Gyau, +3 authors, Silvia Deaglio.
Int J Mol Sci, 2020 Mar 12; 21(5). PMID: 32155826    Free PMC article.
Development of immune checkpoint therapy for cancer.
Jill M Fritz, Michael J Lenardo.
J Exp Med, 2019 May 10; 216(6). PMID: 31068379    Free PMC article.
Highly Cited. Review.
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Ingrid Teige, Linda Mårtensson, Björn L Frendéus.
Front Immunol, 2019 Apr 02; 10. PMID: 30930905    Free PMC article.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Duaa O Khair, Heather J Bax, +22 authors, Sophia N Karagiannis.
Front Immunol, 2019 Apr 04; 10. PMID: 30941125    Free PMC article.
Highly Cited. Review.
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Alexander H Morrison, Mark S Diamond, +2 authors, Robert H Vonderheide.
Proc Natl Acad Sci U S A, 2020 Mar 28; 117(14). PMID: 32213589    Free PMC article.
Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Safa Tahmasebi, Reza Elahi, Abdolreza Esmaeilzadeh.
Stem Cell Rev Rep, 2019 Jun 05; 15(5). PMID: 31161552
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.
Stephanie Dorta-Estremera, Venkatesh L Hegde, +7 authors, K Jagannadha Sastry.
J Immunother Cancer, 2019 Sep 20; 7(1). PMID: 31533840    Free PMC article.
Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.
Candice D Carpenter, Iyad Alnahhas, +2 authors, Vinay K Puduvalli.
Expert Rev Neurother, 2019 May 21; 19(7). PMID: 31106606    Free PMC article.
Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kiran Kundu, Susmita Ghosh, +11 authors, Angel Porgador.
Cancer Immunol Res, 2019 Jun 06; 7(7). PMID: 31164357    Free PMC article.
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Abdulaziz B Hamid, Ruben C Petreaca.
Cancers (Basel), 2020 Apr 15; 12(4). PMID: 32283832    Free PMC article.
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Sanjay S Patel, Jason L Weirather, +6 authors, Scott J Rodig.
Blood, 2019 Nov 08; 134(23). PMID: 31697809    Free PMC article.
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo.
Nat Rev Immunol, 2020 May 21; 20(11). PMID: 32433532    Free PMC article.
Adjuvant Therapy for Melanoma.
Maiko Wada-Ohno, Takamichi Ito, Masutaka Furue.
Curr Treat Options Oncol, 2019 Jun 27; 20(8). PMID: 31236710
Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.
Kristian M Hargadon.
Clin Transl Med, 2020 Jun 09; 10(1). PMID: 32508018    Free PMC article.
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.
Mikołaj Wołącewicz, Rafał Hrynkiewicz, +4 authors, Paulina Niedźwiedzka-Rystwej.
Cancers (Basel), 2020 May 13; 12(5). PMID: 32392774    Free PMC article.
Combining epigenetic and immune therapy to overcome cancer resistance.
Stephanie Gomez, Tomasz Tabernacki, +2 authors, Katherine B Chiappinelli.
Semin Cancer Biol, 2019 Dec 27; 65. PMID: 31877341    Free PMC article.
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.
Rodolfo Daniel Cervantes-Villagrana, Damaris Albores-García, Alberto Rafael Cervantes-Villagrana, Sara Judit García-Acevez.
Signal Transduct Target Ther, 2020 Jun 20; 5(1). PMID: 32555170    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Amblessed E Onuma, Hongji Zhang, +3 authors, Allan Tsung.
Gene Expr, 2020 Apr 29; 20(1). PMID: 32340652    Free PMC article.
CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses.
Phoebe E Lewis, Ethan C Poteet, +6 authors, Qizhi Yao.
Vaccines (Basel), 2020 Jun 11; 8(2). PMID: 32517277    Free PMC article.
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.
Anna Śledzińska, Maria Vila de Mucha, +19 authors, Sergio A Quezada.
Immunity, 2020 Jan 12; 52(1). PMID: 31924474    Free PMC article.
Exploiting NK Cell Surveillance Pathways for Cancer Therapy.
Alexander David Barrow, Marco Colonna.
Cancers (Basel), 2019 Jan 11; 11(1). PMID: 30626155    Free PMC article.
On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.
Benjamin Y Kong, Holly Bolton, +3 authors, Georgina J Clark.
Front Oncol, 2019 Feb 23; 9. PMID: 30788290    Free PMC article.
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.
Karishma R Rajani, Lucas P Carlstrom, +3 authors, Terry C Burns.
Front Oncol, 2019 Mar 12; 8. PMID: 30854331    Free PMC article.
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.
Tao Dao, Sung Soo Mun, +11 authors, David A Scheinberg.
Oncoimmunology, 2019 May 31; 8(7). PMID: 31143508    Free PMC article.
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
Vasileios Atsaves, Vasiliki Leventaki, George Z Rassidakis, Francois X Claret.
Cancers (Basel), 2019 Jul 26; 11(7). PMID: 31340499    Free PMC article.
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab.
Sonam Puri, Joseph Markowitz.
Ann Res Hosp, 2017 May 01; 1. PMID: 31460494    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Ruidi Jiao, Hui Luo, Wenbo Xu, Hong Ge.
Onco Targets Ther, 2019 Sep 26; 12. PMID: 31551657    Free PMC article.
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Grzegorz Sławiński, Anna Wrona, +2 authors, Ewa Lewicka.
Int J Mol Sci, 2020 Oct 03; 21(19). PMID: 33003425    Free PMC article.
CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC).
Shiyi Liu, Feiyan Wang, +10 authors, Yanxiang Cheng.
Cancer Cell Int, 2020 Oct 30; 20. PMID: 33117084    Free PMC article.
Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential Biomarkers.
Suresh Veeramani, George J Weiner.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33066142    Free PMC article.
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Diane M Da Silva, Danielle M Enserro, +10 authors, W Martin Kast.
Clin Cancer Res, 2020 Aug 21; 26(21). PMID: 32816895    Free PMC article.
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Giandomenico Roviello, Martina Catalano, +3 authors, Gabriella Nesi.
Int J Mol Sci, 2020 Oct 30; 21(21). PMID: 33114616    Free PMC article.
The Influence of Tumor Microenvironment on Immune Escape of Melanoma.
Aleksandra Simiczyjew, Ewelina Dratkiewicz, +3 authors, Dorota Nowak.
Int J Mol Sci, 2020 Nov 12; 21(21). PMID: 33171792    Free PMC article.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Caroline Jochems, Jo A Tucker, +6 authors, Jeffrey Schlom.
Cancer Immunol Immunother, 2014 Feb 12; 63(4). PMID: 24514956    Free PMC article.
Combining immunotherapies for the treatment of prostate cancer.
Jason M Redman, James L Gulley, Ravi A Madan.
Urol Oncol, 2017 Nov 18; 35(12). PMID: 29146441    Free PMC article.
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
J M Moskovitz, R L Ferris.
J Dent Res, 2018 Mar 01; 97(6). PMID: 29489423    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Gilda Varricchi, Stefania Loffredo, +6 authors, Maria Rosaria Galdiero.
Int J Mol Sci, 2019 Aug 16; 20(16). PMID: 31412566    Free PMC article.
Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function.
Kathryn A Helmin, Luisa Morales-Nebreda, +9 authors, Benjamin D Singer.
J Clin Invest, 2020 Sep 09; 130(12). PMID: 32897881    Free PMC article.
Noninvasive Imaging of Cancer Immunotherapy.
Omar Abousaway, Taha Rakhshandehroo, +2 authors, Mohammad Rashidian.
Nanotheranostics, 2021 Jan 05; 5(1). PMID: 33391977    Free PMC article.
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Darren J Schofield, Jennifer Percival-Alwyn, +18 authors, Michael Oberst.
MAbs, 2021 Jan 06; 13(1). PMID: 33397194    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Minimal Residual Disease, Metastasis and Immunity.
Jordi Badia-Ramentol, Jenniffer Linares, Andrea Gómez-Llonin, Alexandre Calon.
Biomolecules, 2021 Jan 28; 11(2). PMID: 33498251    Free PMC article.
PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
Christopher D Nishimura, Marc C Pulanco, +2 authors, Xingxing Zang.
Trends Mol Med, 2020 Nov 18; 27(3). PMID: 33199209    Free PMC article.
Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.
Pilar Martín, Rafael Blanco-Domínguez, Raquel Sánchez-Díaz.
Cell Mol Immunol, 2020 Nov 26; 18(4). PMID: 33235388    Free PMC article.
Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.
Helaina C Regen-Tuero, Robert C Ward, William M Sikov, Peter J Littrup.
Radiol Imaging Cancer, 2021 Apr 06; 3(2). PMID: 33817653    Free PMC article.
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.
Krishna Patel, Sohail Siraj, +3 authors, Riyaz Basha.
Crit Rev Oncog, 2019 Nov 05; 24(2). PMID: 31679206    Free PMC article.
Emerging strategies for treating metastasis.
Mark Esposito, Shridar Ganesan, Yibin Kang.
Nat Cancer, 2021 Apr 27; 2(3). PMID: 33899000    Free PMC article.
Metabolism of Immune Cells in the Tumor Microenvironment.
Jin G Jung, Anne Le.
Adv Exp Med Biol, 2021 May 21; 1311. PMID: 34014543
Identification of CTLA-4-Positive Cells in the Human Tonsil.
Markus Tiemann, Dmitri Atiakshin, Vera Samoilova, Igor Buchwalow.
Cells, 2021 May 01; 10(5). PMID: 33925389    Free PMC article.
CTLA-4 +49 A/G Polymorphism and the Risk of Lung Cancer: a Meta-analysis.
Zhengliang Wei, Shaoqin Zhang, Jian Hu.
Zhongguo Fei Ai Za Zhi, 2021 Apr 06; 24(3). PMID: 33819967    Free PMC article.
Systematic Review.
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Patrizia Leone, Antonio Giovanni Solimando, +7 authors, Vito Racanelli.
Vaccines (Basel), 2021 Jun 03; 9(5). PMID: 34065489    Free PMC article.
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.
Eric Alves, Shahama Taifour, +4 authors, Pilar Blancafort.
Mol Ther Methods Clin Dev, 2021 Jun 08; 21. PMID: 34095343    Free PMC article.

;. PMID: 34098941
Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.
Yara Abdou, Manu Pandey, +3 authors, Marc S Ernstoff.
Br J Clin Pharmacol, 2020 Apr 24; 86(9). PMID: 32323342    Free PMC article.
Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view.
Xingyue Huang, Yang Lu, +2 authors, Ning Han.
Theranostics, 2021 Jun 24; 11(15). PMID: 34158866    Free PMC article.
Protamine-Based Strategies for RNA Transfection.
Natalia Teresa Jarzebska, Mark Mellett, +2 authors, Steve Pascolo.
Pharmaceutics, 2021 Jul 03; 13(6). PMID: 34198550    Free PMC article.
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Julie M Collins, Jason M Redman, James L Gulley.
Expert Rev Vaccines, 2018 Jul 31; 17(8). PMID: 30058393    Free PMC article.
Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review.
Heidi Jones, Victoria Green, James England, John Greenman.
Future Sci OA, 2021 Jul 15; 7(7). PMID: 34258030    Free PMC article.
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.
Bonnie L Russell, Selisha A Sooklal, +2 authors, Monde Ntwasa.
Front Oncol, 2021 Jul 17; 11. PMID: 34268109    Free PMC article.
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
Chang-Gon Kim, Yun-Beom Sang, Ji-Hyun Lee, Hong-Jae Chon.
Int J Mol Sci, 2021 Aug 08; 22(15). PMID: 34360800    Free PMC article.
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Yang Ge, Huiyun Zhang, Nathaniel Weygant, Jiannan Yao.
Front Pharmacol, 2021 Aug 28; 12. PMID: 34447305    Free PMC article.
The State of Immunotherapy in Hepatobiliary Cancers.
Farhan Z Ilyas, Joal D Beane, Timothy M Pawlik.
Cells, 2021 Aug 28; 10(8). PMID: 34440865    Free PMC article.
Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Jasmine Huynh, Kanishka Patel, +4 authors, Samuel Klempner.
Curr Treat Options Oncol, 2021 Sep 16; 22(11). PMID: 34524553
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Xiao-Jun Guo, Jia-Cheng Lu, +17 authors, Xiao-Yong Huang.
Front Immunol, 2021 Sep 17; 12. PMID: 34526987    Free PMC article.
Targeting the spectrum of immune checkpoints in prostate cancer.
Laura A Sena, Samuel R Denmeade, Emmanuel S Antonarakis.
Expert Rev Clin Pharmacol, 2021 Jul 16; 14(10). PMID: 34263692    Free PMC article.
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients.
Lu Meng, Jianfang Xu, +3 authors, Xiaomei Gong.
Front Immunol, 2021 Oct 09; 12. PMID: 34621270    Free PMC article.
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer.
Chang Woo Kim, Hong Jae Chon, Chan Kim.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638390    Free PMC article.
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
Jonathan Marable, Damien Ruiz, +8 authors, Maninder Sandey.
Sci Rep, 2021 Oct 23; 11(1). PMID: 34675296    Free PMC article.
Immunotherapies for hepatocellular carcinoma.
Josep M Llovet, Florian Castet, +6 authors, Richard S Finn.
Nat Rev Clin Oncol, 2021 Nov 13; 19(3). PMID: 34764464
Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery.
Marisa Market, Gayashan Tennakoon, Rebecca C Auer.
Int J Mol Sci, 2021 Nov 14; 22(21). PMID: 34768810    Free PMC article.
Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
R R Maniyar, S Chakraborty, +4 authors, R K Tiwari.
Adv Exp Med Biol, 2021 Dec 11; 1350. PMID: 34888847
SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.
Patricia Balsas, Luis Veloza, +16 authors, Virginia Amador.
Blood, 2021 Jul 01; 138(22). PMID: 34189576    Free PMC article.
Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy.
Nicolas Jacquelot, Maryam Ghaedi, +3 authors, Pamela S Ohashi.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34885076    Free PMC article.
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Elena Goleva, Taras Lyubchenko, +3 authors, Jeffrey A Kern.
Ann Allergy Asthma Immunol, 2021 Mar 16; 126(6). PMID: 33716146    Free PMC article.
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma.
A-Reum Kim, Seong Jin Choi, +9 authors, Eui-Cheol Shin.
Oncoimmunology, 2022 Jan 18; 11(1). PMID: 35036078    Free PMC article.
The cGAS/STING Pathway: A Novel Target for Cancer Therapy.
Yu Gan, Xiaoying Li, +5 authors, Wei Li.
Front Immunol, 2022 Jan 21; 12. PMID: 35046953    Free PMC article.
The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Huan Tong, He Wei, Alhaji Osman Smith, Juan Huang.
Front Immunol, 2022 Jan 25; 12. PMID: 35069586    Free PMC article.
CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.
Zhongkun Zhang, Jimmy Chun-Tien Kuo, +3 authors, Robert J Lee.
Pharmaceutics, 2022 Jan 22; 14(1). PMID: 35056969    Free PMC article.
microRNA-128-3p inhibits CD4+ regulatory T cells enrichment by targeting interleukin 16 in gastric cancer.
Weidan Fang, Chao Shi, +2 authors, Ling Zhang.
Bioengineered, 2021 Dec 31; 13(1). PMID: 34968167    Free PMC article.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Ding Hu, Qingfei Cao, +8 authors, Huashan Zhang.
BMC Med Genomics, 2022 Feb 10; 15(1). PMID: 35135561    Free PMC article.
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Grazia Graziani, Lucia Lisi, Lucio Tentori, Pierluigi Navarra.
Exp Suppl, 2022 Feb 16; 113. PMID: 35165868
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Yosuke Sato, Cierra N Casson, +14 authors, Michael H Shaw.
Cancer Immunol Immunother, 2022 Mar 04;. PMID: 35237846
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
Megan M Y Hong, Saman Maleki Vareki.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326731    Free PMC article.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer.
Yohei Asano, Norio Yamamoto, +13 authors, Hiroyuki Tsuchiya.
Front Oncol, 2022 Apr 19; 12. PMID: 35433422    Free PMC article.
The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
Ze Zhang, Furong Liu, +6 authors, Zhanguo Zhang.
Exp Hematol Oncol, 2022 May 20; 11(1). PMID: 35590394    Free PMC article.